bluebird bio, Inc. (0HOH.L)
USD 8.02
(1.01%)
USD 8.02
(1.01%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -4.03 Million USD | 37.81% |
| 2022 | -6.48 Million USD | 81.59% |
| 2021 | -35.19 Million USD | -114.35% |
| 2020 | 245.33 Million USD | 488.4% |
| 2019 | 41.69 Million USD | -22.35% |
| 2018 | 53.69 Million USD | 58.39% |
| 2017 | 33.9 Million USD | 117.07% |
| 2016 | -198.62 Million USD | -81.13% |
| 2015 | -109.65 Million USD | -195.16% |
| 2014 | -37.15 Million USD | -243.34% |
| 2013 | -10.82 Million USD | 35.86% |
| 2012 | -16.87 Million USD | -2012.7% |
| 2011 | 882 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -7.29 Million USD | -305.51% |
| 2024 Q2 | -12.84 Million USD | -76.18% |
| 2023 Q3 | 1.43 Million USD | 153.74% |
| 2023 Q2 | -2.67 Million USD | -168.74% |
| 2023 Q1 | -995 Thousand USD | -2587.5% |
| 2023 Q4 | -1.79 Million USD | -225.12% |
| 2023 FY | -4.03 Million USD | 37.81% |
| 2022 Q3 | -1.31 Million USD | -482.3% |
| 2022 FY | -6.48 Million USD | 81.59% |
| 2022 Q2 | -226 Thousand USD | 96.45% |
| 2022 Q1 | -6.36 Million USD | -206.6% |
| 2022 Q4 | 40 Thousand USD | 103.04% |
| 2021 Q3 | 2.97 Million USD | 116.61% |
| 2021 Q4 | -2.07 Million USD | -169.83% |
| 2021 FY | -35.19 Million USD | -114.35% |
| 2021 Q2 | -17.9 Million USD | -270.27% |
| 2021 Q1 | 10.51 Million USD | 14.16% |
| 2020 Q3 | 17.95 Million USD | -90.9% |
| 2020 Q1 | 20.83 Million USD | 133.51% |
| 2020 Q2 | 197.33 Million USD | 847.0% |
| 2020 FY | 245.33 Million USD | 488.4% |
| 2020 Q4 | 9.2 Million USD | -48.71% |
| 2019 FY | 41.69 Million USD | -22.35% |
| 2019 Q1 | 12.04 Million USD | -34.65% |
| 2019 Q2 | 12.68 Million USD | 5.33% |
| 2019 Q4 | 8.92 Million USD | 10.88% |
| 2019 Q3 | 8.04 Million USD | -36.54% |
| 2018 FY | 53.69 Million USD | 58.39% |
| 2018 Q4 | 18.42 Million USD | 60.23% |
| 2018 Q3 | 11.49 Million USD | 46.86% |
| 2018 Q2 | 7.83 Million USD | -50.88% |
| 2018 Q1 | 15.94 Million USD | 283.08% |
| 2017 Q3 | 6.61 Million USD | -59.43% |
| 2017 FY | 33.9 Million USD | 117.07% |
| 2017 Q2 | 16.29 Million USD | 133.81% |
| 2017 Q1 | -48.19 Million USD | 31.72% |
| 2017 Q4 | 4.16 Million USD | -37.06% |
| 2016 Q2 | -40.2 Million USD | 0.5% |
| 2016 Q1 | -40.41 Million USD | -88.96% |
| 2016 Q3 | -47.41 Million USD | -17.93% |
| 2016 Q4 | -70.58 Million USD | -48.85% |
| 2016 FY | -198.62 Million USD | -81.13% |
| 2015 Q1 | -17.37 Million USD | -22.83% |
| 2015 FY | -109.65 Million USD | -195.16% |
| 2015 Q2 | -30.82 Million USD | -77.42% |
| 2015 Q3 | -29.07 Million USD | 5.69% |
| 2015 Q4 | -21.38 Million USD | 26.43% |
| 2014 FY | -37.15 Million USD | -243.34% |
| 2014 Q3 | -10.28 Million USD | -35.39% |
| 2014 Q4 | -14.14 Million USD | -37.54% |
| 2014 Q1 | -5.12 Million USD | -49.5% |
| 2014 Q2 | -7.59 Million USD | -48.13% |
| 2013 Q2 | -913 Thousand USD | 78.04% |
| 2013 Q4 | -3.43 Million USD | -47.78% |
| 2013 FY | -10.82 Million USD | 35.86% |
| 2013 Q1 | -4.15 Million USD | 35.17% |
| 2013 Q3 | -2.32 Million USD | -154.22% |
| 2012 Q3 | -3.41 Million USD | -4118.82% |
| 2012 Q2 | 85 Thousand USD | 0.0% |
| 2012 Q1 | 85 Thousand USD | 0.0% |
| 2012 Q4 | -6.41 Million USD | -87.7% |
| 2012 FY | -16.87 Million USD | -2012.7% |
| 2011 FY | 882 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | 281.941% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 1434.437% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 95.271% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 123.269% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | -1187.54% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 127.241% |
| Imunon, Inc. | -720 Thousand USD | -459.718% |
| Dynavax Technologies Corporation | 182.11 Million USD | 102.213% |
| Editas Medicine, Inc. | -99.52 Million USD | 95.951% |
| FibroGen, Inc. | 128.9 Million USD | 103.126% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 57.872% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -1230.033% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 100.218% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 100.369% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 100.769% |
| Verastem, Inc. | -62 Thousand USD | -6400.0% |
| Zoetis Inc. | 5.83 Billion USD | 100.069% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.047% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 91.109% |
| Homology Medicines, Inc. | -7.22 Million USD | 44.252% |
| Nektar Therapeutics | 53.47 Million USD | 107.536% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -1280.137% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 79.542% |
| Perrigo Company plc | 1.68 Billion USD | 100.24% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 105.515% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.015% |
| Illumina, Inc. | 2.74 Billion USD | 100.147% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.026% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 100.077% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 140.131% |
| Waters Corporation | 1.76 Billion USD | 100.229% |
| Biogen Inc. | 7.3 Billion USD | 100.055% |
| Evolus, Inc. | 140.52 Million USD | 102.868% |
| Adicet Bio, Inc. | -6.09 Million USD | 33.913% |
| Geron Corporation | -123.5 Million USD | 96.737% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 100.266% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 101.113% |
| Myriad Genetics, Inc. | 476.4 Million USD | 100.846% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 98.989% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 100.186% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 87.07% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 100.212% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.036% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 100.116% |
| OPKO Health, Inc. | 318.12 Million USD | 101.267% |
| Exelixis, Inc. | 1.75 Billion USD | 100.229% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 100.847% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 101.648% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 100.518% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 100.633% |
| Blueprint Medicines Corporation | 236.58 Million USD | 101.703% |
| Insmed Incorporated | 239.63 Million USD | 101.682% |
| TG Therapeutics, Inc. | 219.1 Million USD | 101.839% |
| Incyte Corporation | 3.44 Billion USD | 100.117% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 101.172% |